![]() ![]() ![]() Our deep and diverse product pipeline, commercial execution and financial flexibility provide a strong foundation that is enabling the company to bring new medicines that benefit patients with serious unmet needs, drive in-line product performance and deliver sustained growth.” “Our teams advanced the product portfolio and achieved significant regulatory and clinical milestones, including for the fixed-dose combination of relatlimab and nivolumab. “Our strong results reflect increased adoption of our new product portfolio and continued demand growth across all four core therapeutic areas,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. NEW YORK-(BUSINESS WIRE)- Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2021, which reflect solid sales, strong commercial execution and continued progress of the company’s pipeline. Adjusts GAAP and Raises Lower-End of Non-GAAP EPS Guidance Range for 2021.Achieves FDA Priority Review for Third Distinct Checkpoint Inhibitor, Relatlimab and Nivolumab Fixed-Dose Combination , as Treatment for Patients with Unresectable or Metastatic Melanoma.Advances Product Pipeline with Significant Regulatory and Clinical Milestones.Posts Third Quarter Earnings Per Share of $0.69 and Non-GAAP EPS of $2.00.Reports Third Quarter Revenues of $11.6 Billion, an Increase of 10% YoY.
0 Comments
Leave a Reply. |